Interim report
Page 1
@) Divi 's Laboratories Limited To The Secretary National Stock Exchange of India Limited Exchange Plaza, Bandra-Kurla Complex, Bandra (East) Mumbai - 400 051 Trading Symbol: DIVISLAB Dear Sir/ Madam, Date: November 07, 2025 To The Secretary BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street Mumbai - 400 001 Scrip Code: 532488 Sub: Outcome of Board Meeting held on November 07, 2025 Ref: Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 Further to our intimation dated October 27, 2025, we would like to inform that the Board of Directors of the Company at its meeting held on November 07, 2025, has approved, inter alia, the following items of business: Financial Results Approved the statement of unaudited financial results, standalone and consolidated, for the quarter and half year ended September 30, 2025. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we are enclosing herewith the following: 1. Statement of standalone unaudited financial results for the quarter and half year ended September 30, 2025 and Limited Review Report of the Statutory Auditors thereon. 2. Statement of consolidated unaudited financial results for the quarter and half year ended September 30, 2025 and Limited Review Report of the Statutory Auditors thereon. 3. Press release on the financial results of the Company. Changes in Senior Management Personnel Approved change in designation of Mr. Nimmagadda Venkata Anirudh as President (Nutraceuticals) and Senior Management Personnel of the Company with effect from November 07, 2025, as recommended by the Nomination and Remuneration Committee. The particulars in relation to the said changes in Senior Management Personnel as required pursuant to SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0 155 November 11, 2024, is enclosed as Annexure - I. Regd. Off.: Divi Towers, 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad - 500 032, Telangana, INDIA. Tel : +91-40-6696 6300/400, Fax : 91-40-6696 6460., CIN : L24110TG1990PLC011854 E-mail: mail@divislabs.com, Website: www.divislabs.com
Page 2
@i) Divi 's Laboratories Limited The Board meeting commenced at 10.30 Hrs and concluded at 11.45 Hrs. This is for your information and records. Thanking you, Yours faithfully, For Divi's Laboratories Limited M. Satish Choudhury Company Secretary & Compliance Officer Regd. Off. : Divi Towers, 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad - 500 032, Telangana, INDIA. Tel: +91-40-6696 6300/400, Fax: 91-40-6696 6460., CIN: L24110TG1990PLC011854 E-mail: mail@divislabs.com, Website: www.divislabs.com
Page 3
(¥jjji) Divi 's Laboratories Limited Name Reason for change Date of Appointment and term of appointment Brief Profile (in case of appointment) Disclosure of relationship between directors Annexure-1 Mr. Nimmagadda Venkata Anirudh Mr. Anirudh is designated as President (Nutraceuticals) and Senior Management Personnel with effective from November 07, 2025. He will be heading the entire nutraceutical business of the Company and will be reporting directly to the Chief Executive Officer of the Company. November 07, 2025. Term of appointment: Full-time emplovment. Mr. Anirudh studied B.E. Mechanical Engineering and has done certification programmes on Strategic Marketing from Harvard University in Boston, on Investments from Indian Institute of Management in Ahmedabad, and on Family Office Management and Business Management from Jarnnalal Bajaj Institute of Management Studies in Mumbai. He joined Divi's Laboratories Limited in the year 2014 as the Relationship Manager for all the customers in the US & Canada region. Post his role as Relationship Manager - USA, he was tasked with handling the Indian customers manufacturing the finished dose formulations for the global markets along with the MNC customers that Divi's was working with on the generic side of the business. In September 2022, he was promoted as Head of Nutraceuticals. In his role, he was assigned to maximize the sales potential for each of the nutraceutical ingredients, identification of new ingredients to the Company's portfolio, improve operational efficiencies, optimise raw material procurement and oversee the subsidiaries operations in USA and Switzerland. Mr. Anirudh is son of Mr. N.V. Rarnana, Executive Director of the Company. Regd. Off.: Divi Towers, 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad - 500 032, Telangana, INDIA. Tel: +91-40-6696 6300/400, Fax: 91-40-6696 6460., CIN: L24110TG1990PLC011854 E-mail: mail@divislabs.com, Website: www.divislabs.com
Page 4
DIVl'S LABORATORIES LIMITED STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30™ SEPTEMBER,2025 (Rs. in Crores) Quarter ended s. Particulars 30.09.2025 30.06.2025 No. (Unaudited) (Unaudited) 1 Income Revenue from operations 2660 2357 Other income 146 119 Total income 2806 2476 2 Expenses a) Cost of materials consumed 907 989 b) Purchases of stock-in-trade " - c) Changes in inventories of finished goods, work-in- progress and stock-in-trade 144 (72) d) Employee benefits expense 344 330 e) Depreciation and amortisation expense 113 112 f) Finance costs 8 3 g) Other expenses 370 367 Total expenses 1886 1729 3 Profit before exceptional Items and tax (1-2) 920 747 4 Exceptional items " " 5 Profit before tax (3-4) 920 747 6 Tax expense a) Current tax 220 191 b) Deferred tax 4 (1) Total tax expense 224 190 7 Profit for the period/year (5- 6) 696 557 8 Other comprehensive income: Items that will not be reclassified to Profit or Loss: (i) Gain/(Loss) on Remeasurement of post- emplovment benefit obligation -* (1) (ii) Income tax relating to the above -* -* Total other comprehensive income (i+ii) -* (]) 9 Total comprehensive income for the period/year (7+8) 696 556 10 Paid-up Equity Share Capital (Face Value: Rs. 2/- per share) 53 53 11 Other equity excluding revaluation reserve 12 Earnings per Share # (Face Value: Rs. 2/- per share) (not annualized) a) Basic (Rs.) 26.24 20.95 b) Diluted (Rs.) 26.24 20.95 #Earnings per share calculated on actual amount of profit after tax in rupees * Amount is below the rounding off norms adopted by the company. Half Year ended Year ended 30.09.2024 30.09.2025 30.09.2024 31.03.2025 (Unaudited) (Unaudited) (Unaudited) (Audited) 2302 5017 4365 9198 105 265 183 352 2407 5282 4548 9550 953 1896 1835 3760 " - - - 1 72 (55) (83) 296 674 581 1210 98 225 195 401 l 11 l 1 323 737 653 1332 1672 3615 3210 6621 735 1667 1338 2929 - " - " 735 1667 1338 2929 218 411 396 793 (1) 3 (6) (73) 217 414 390 720 518 1253 948 2209 -* (1) (l) (3) -* -* -* 1 -* (1) (l) (2) 518 1252 947 2207 53 53 53 53 14842 19.51 47.19 35.69 83.20 19.51 47.19 35.69 83.20
Page 5
S. No. A 1 2 B 1 2 3 DIVl'S LABORATORIES LIMITED STATEMENT OF STANDALONE UNAUDITED ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER,2025 (Rs. in Crores) As at Particulars 30.09.2025 31.03.2025 (Unaudited) (Audited) ASSETS Non-current assets Property , plant and equipment 5671 5436 Capital work-in-progress 2030 1022 Intangible assets 4 4 Financial assets a) Investments 74 72 b) Other financial assets 65 62 Income tax assets (net) 1 1 Other non-current assets 452 248 Sub-total: Non-current assets 8297 6845 Current assets Inventories 3240 3033 Financial assets a) Trade receivables 2773 2855 b) Cash and cash eauivalents 61 396 c) Bank balances other than (b) above 3178 3300 d) Other financial assets 8 16 Income-tax assets (net) 14 12 Other current assets 504 367 Sub-total: Current assets 9778 9979 TOT AL ASSETS 18075 16824 EQUITY AND LIABILITIES Equitv Equity Share Capital 53 53 Other Equity 15298 14842 Sub-total: Total Equity 15351 14895 Liabilities Non-current liabilities Financial liabilities a) Other financial liabilities 274 - Other non-current liabilities 224 - Deferred tax liabilities (net) 512 509 Sub-total: Non-current liabilities 1010 509 Current liabilities Financial liabilities a) Borrowings 89 2 b) Trade payables Total outstanding dues of micro and small enterprises 9 37 Total outstanding dues other than above 1024 843 c) Other financial liabilities 266 134 Current tax liabilities (net) 45 - Other current liabilities 220 350 Provisions 61 54 Sub-total: Current liabilities 1714 1420 Total Liabilities 2724 1929 TOT AL EQUITY AND LIABILITIES 18075 16824
Page 6
DIVl'S LABORATORIES LIMITED STATEMENT OF STANDALONE UNAUDITED CASH FLOWS FOR THE HALF YEAR ENDED 30th SEPTEMBER 2025 (Rs. in Crores) For the Half year ended For the year ended Particulars 30.09.2025 30.09.2024 31.03.2025 (Unaudited) (Unaudited) (Audited) A. Cash flow from operating activities Profit before tax 1667 1338 2929 Adjustments for: Depreciation and amortisat ion expense 225 195 401 Unrealised foreign exchange (gain)/ loss (44) (14) 6 Interest income from financial assets at amortised cost (157) (152) (295) Change in fair value of investment in optionally convertible debentures (2) (3) (I) Gain on redemption of investments - - (4) Interest expense 5 -* 1 Provision for doubtful debts / (written back) including bad debts written off 2 1 1 /(recovered) Loss/(gain) on disposal/ discard of property, plant and equipment and intangible -* 4 4 assets Amortisation of government grants -* -* -* 1696 1369 3042 Change in operating assets and liabilities (Increase) /Decrease in trade receivables 150 18 (592) (Increase) /Decrease in inventories (207) 27 (48) (Increase) /Decrease in other non-current assets -* - - (Increase) /Decrease in other non-current financial assets (3) 1 (6) (Increase) /Decrease in other current financial assets 8 (6) (9) (Increase) /Decrease in other current assets (137) (66) (49) Increase /(Decrease) in employee benefit obligation 6 3 7 Increase /(Decrease) in trade payables 147 16 82 Increase / (Decrease) in other non-current financial liabilities 260 - - Increase / (Decrease) in other non-current liabilities 224 - - Increase/ (Decrease) in other current financial liabilities -* - - Increase /(Decrease) in other current liabilities (136) (64) 41 Cash generated from operations 2008 1298 2468 Income taxes paid including withholding tax and net of refunds (368) (364) (818) Net cash inflow from operating activities 1640 934 1650 B. Cash flow from investing activities Payments for property, plant and equipment (1544) (662) (1437) Proceeds from sale of property, plant and equipment 3 - -* Proceeds from redemption of optionally convertible debentures - - 22 Interest received 158 152 295 Proceeds from withdrawal of deposits 2855 1002 3541 Investment in deposits (2733) (949) (3224) Net cash outflow from investing activities (1261) (457) (803)
Page 7
DIVl'S LABO RA TORIES LIMITED STATEMENT OF STANDALONE UNAUDITED CASH FLOWS FOR THE HALF YEAR ENDED 30th SEPTEMBER 2025 (Rs. in Crores) For the Half year ended For the year ended Particulars 30.09.2025 30.09.2024 31.03.2025 (Unaudited) (Unaudited) (Audited) C. Cash flow from financing activities Proceeds /(repayment) of working capital loans (net) 83 5 - Interest paid (5) (1) (1) Dividend paid to company's shareholders (796) (796) (796) Net cash outflow from financing activities (718) (792) (797) Net increase/(decrease) in cash and cash equivalents (A+B+C) (339) (315) 50 Cash and cash equivalents at the beginning of the period/year 394 344 344 Cash and cash equivalents at end of the period/year 55 29 394 Reconciliation of cash and cash equivalents at the end of the period/ year Cash and cash equivalents as per Balance sheet 61 29 396 Overdraft facilities from bank (6) - (2) Balances as per Statement of cash flows 55 29 394 * Amount is below the rounding off norms adopted by the company. Notes: 1. The above Statement of Standalone Unaudited Financial Results for the quarter and half year ended 30th September, 2025, Statement of Standalone Unaudited Assets and Liabilities as at 30th September, 2025 and Statement of Standalone Unaudited Cash Flows for the half year ended 30th September, 2025 ('Standalone Statement') are prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. This Standalone Statement has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on November 07, 2025. The statutory auditors have carried out a limited review of this Standalone Statement and issued an unmodified report thereon. 2. The Company is engaged in the manufacture of Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients and the same constitutes a single reportable business segment as per Ind AS 108. 3. The Company does not have any discontinued operations and the profit for the period represents the profits from continuing operations only. 4. Details ofForex gain are as given below: Quarter ended 30.09.2025 I 30.06.2025 I 30.09.2024 Forex gain 64 I 39 I 27 Forex gain has been included in other income. (Rs. in Crores) Half Year ended 30.09.2025 I 30.09.2024 103 I 26 For Divi's Laboratories Limited ~~ Dr. Kirao S Divi Whole-time Director and Chief Executive Officer Year ended 31.03.2025 48
Page 8
Price Waterhouse Chartered Accountants LLP Review Report To The Board of Directors M/s Divi's Laboratories Limited Divi Towers, 1-72/23(P)/303, Cyber Hills, Gachibowli, Hyderabad, 500032 1. We have reviewed the standalone unaudited financial results of Divi's Laboratories Limited (the "Company") for the quarter ended September 30, 2025 and the year to date results for the period April 01, 2025 to September 30, 2025, which are included in the accompanying Statement of Standalone Unaudited Financial Results for the quarter and half year ended September 30, 2025, the Statement of Standalone Unaudited Assets and Liabilities as on that date and the Statement of Standalone Unaudited Cash Flows for the half year ended on that date (the "Standalone Statement"). The Standalone Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes. This Standalone Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Standalone Statement based on our review. 2. We conducted our review of the Standalone Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Standalone Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Standalone Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement. For Price Waterhouse Chartered Accountants LLP Firm Registration Number: 012754N/N500016 c::)rn-~-.) ---Q.l~"' N.K. Varadarajan Partner Membership Number: 90196 UDIN: 25090196BMRJSN8995 Place: Hyderabad Date: November 07, 2025 Price Waterhouse Chartered Accountants LLP, Unit - 2B, 8th Floor, Octave Block, Block El, Parcel - 4, Salarpuria Sattva Knowledge City, Raidurg, Hyderabad, Telangana - 500081 T: +91 (40) 44246740 Registered office and Head office: 11-A, Vishnu Digamber Marg, Sucheta Bhawan, New Delhi - 110002 Price Waterhouse (a Partnership Firm) converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-5001) with effect from July 25, 2014. Post its conversion to Price Waterhouse Chartered Accountants LLP, its ICAI registration number is 012754N/NS00016 (ICAI registration number before conversion was 012754N)
Page 9
s. No I 2 3 4 5 6 7 8 9 10 11 12 13 14 15 DIVl'S LA BORA TORIES LIMITED STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30™ SEPTEMBER,2025 ms in Crores) . Quarter ended Half Year ended Particulars 30.09.2025 30.06.2025 30.09.2024 30.09.2025 30.09.2024 Unaudited Unaudited Unaudited Unaudited Unaudited Income Revenue from operations 2715 2410 2338 5125 4456 Other income 145 119 106 264 184 Total income 2860 2529 2444 5389 4640 Exoenses a) Cost of materials consumed 937 1010 976 1947 1869 b) Purchases of stock-in-trade - - - - - c) Changes in inventories of finished goods, work-in-progress and stock-in- (54) trade 136 (7) 82 (47) d) Employee benefits expense 354 340 304 694 596 e) Depreciation and amortisation expense 113 112 99 225 196 f) Finance costs 8 3 1 11 1 g) Other expenses 400 385 349 785 699 Total expenses 1948 1796 1722 3744 3314 Profit before exceptional items and tax 0-2) 912 733 722 1645 1326 Exceptional items - - - - - Profit before tax (3-4) 912 733 722 1645 1326 Tax expense a) Current tax 220 191 218 411 397 b) Deferred tax 3 (3) (6) -* (11) Total tax expense 223 188 212 411 386 Profit for the period/year (5-6) 689 545 510 1234 940 Profit for the period/year attributable to: Shareholders of the Compan y 689 545 510 1234 940 Non-Controlling Interest - - - - - Other Comprehensive Income: a) Items that will not be reclassified to profit or loss: i) Gain/(loss) on Remeasurement of post-employment benefit obligations -* (l) - (1) ( \ ) ii) Income tax relating to the above -* -* - -* -* b) Items that will be reclassified to profit or loss: i) Gain on exchange differences in translating the financial statements of foreign operations 5 4 2 9 4 ii) Income tax relating to the above (2) -* (I) (2) (1) Total other comprehensive income (a+b) 3 3 1 6 2 Total other comprehensive income for the period/ year attributable to: Shareholders of the Company 3 3 1 6 2 Non-Controlling Interest - - - - - Total comprehensive income for the oeriod/vear (7+9) 692 548 511 1240 942 Total comprehensive income for the period/ year attributable to: Shareholders of the Company 692 548 511 1240 942 Non-Controlling Interest - - - - - Paid-up Equity Share Capital (Face Value: Rs. 2/- per share) 53 53 53 53 53 Other equity excluding revaluation reserve Earnings per Share # (Face Value: Rs. 2/- per share) (not annualized}.-- - - ··:::ft..:::::- a) Bas~ £F,,: l,i : • - . ...:~ ,1c-col 25.97 20.49 19.20 46.46 35.iio,- b) Dil}'~~ :\!l'I •': 1 ,., •,:~ -,~- , 25.97 20.49 19.20 46.46 ., /:3)}~~ Year ended 31.03.2025 Audited 9360 352 9712 3821 - (96) 1243 402 2 1424 6796 2916 - 2916 799 (74) 725 2191 2191 - (3) 1 6 (1) 3 3 - 2194 2194 - 53 14916 :;:-·, 82.53 ..... ~',· , ... 82 53 · " ,\. . # Eami~~ ~ ltis;hare calculat ed.on act ati,!!lt 1 nt of profit after tax in rupees ~ fl-· ( .r,~ ( ) \\ * Amo f.l. 6eto~ ~ - nqing)0 ~ s adopted by the group. ! • > !I' ; } :-.) v, .L.. •l , , .,v c,"- ·o ; .r., ✓- 1 • • * .. ' * I·l_yd ,·: ,,\ ,;,<\ .. ,,__....., ·.' - • ~- C,'., :rJt ✓ //
Page 10
S.No. A 1 2 B 1 2 3 DIVl'S LA BORA TORIES LIMITED STATEMENT OF CONSOLIDATED UNAUDITED ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER ,2025 (Rs . in Crores) As at Particulars 30.09.2025 31 .03.2025 (Unaudited) (Audited) ASSETS Non-current assets Property , plant and equipment 5672 5437 Right of use assets 2 1 Capital work-in-progress 2030 1022 Intangible assets 4 4 Financial assets a) Investments 67 65 b) Other financial assets 65 62 Income tax assets (net) 4 1 Deferred tax asset 12 11 Other non-current assets 452 248 Sub-total: Non-current assets 8308 6851 Current assets Inventories 3433 3236 Financial assets a) Trade receivables 2614 2731 b) Cash and cash equivalents 83 415 c) Bank balances other than (b) above 3178 3300 d) Other financial assets 8 16 Income-tax assets (net) 14 13 Other current assets 513 370 Sub-total: Current assets 9843 10081 TOT AL ASSETS 18151 16932 EQUITY AND LIABILITIES Equity Equity Share Capital 53 53 Other Equity 15360 14916 Sub-total: Total Equity 15413 14969 Liabilities Non-current liabilities Financial liabilities a) Lease liabilities -* 2 b) Other financial liabilities 274 - Other non-current liabilities 224 - Deferred tax liabilities (net) 512 509 Sub-total: Non-current liabilities 1010 511 Current liabilities Financial liabilities a) Borrowings 89 2 b) Lease liabilities 1 -* c) Trade payables Total outstanding dues of micro and small enterprises 9 37 Total outstanding dues other than above 1031 873 d) Other financial liabilities 267 134 Current tax liabilities (net) 45 - Other current liabilities 224 352 Provisions 62 54 Sub-total: Current liabilities 1728 1452 Total Liabilities 2738 1963 TOTAL EQUITY AND LIABILITIES 18151 - .,,.-· 0 ~ • ..:.:::::,,16932 * Amounti~lo.i-v.:: th rounding off norms adopted by the group. / \. J' "'' "" ).:--' . ,/...-.. '•':~\\ <;_: .,,c Ch ~r ,, i·d .,1 ,;~·
Page 11
DIVl'S LABORATORIES LIMITED STATEMENT OF CONSOLIDATED UNAUDITED CASH FLOWS FOR THE HALF YEAR ENDED 301h SEPTEMBER 2025 Particulars A. Cash flow from operating activities Profit before tax Adjustment s for: Depreciation and amortisation expe·nse Unrealised foreign exchange (gain)/ loss Interest income from financial assets at amorti sed cost Change in fair value of investment in optionally convertible debentures Gain on redemption of investments Interest expense Provision for doubtful debts / (written back) including bad debts written off /(recovered) Loss/(gain) on disposal / discard of property, plant and equipment and intangible assets Amortisation of government grants Change in operating assets and liabilities {Increase) /Decrease in trade receivables (Increase) /Decrease in inventories (Increase) /Decrease in other non-current assets (Increase) /Decrease in other non-current financial assets (Increase) /Decrease in other current financial assets (Increase) /Decrease in other current assets Increase /(Decrease) in employee benefit obligation Increase /(Decrease) in trade payables Increase / (Decrease) in other non-current financial liabilities Increase / (Decrease) in other non-current liabilities Increase/ (Decrease) in other current financial liabilities Increase /(Decrease) in other current liabilities Cash generated from operations Income taxes paid including withholding tax and net of refunds Net cash inflow from operating activities B. Cash flow from investing activities Payments for property, plant and equipment Proceeds from sale of property, plant and equipment Proceeds from redemption of optionally convertible debentures Interest received Proceeds from withdrawal of deposits Investment in deposits Net cash outflow from investing activities (Rs. in Crores) For the Half year ended 30.09.2025 (Unaudited) 1645 225 (40) (157) (2) - 5 1 * - * - 1677 188 (197) * - (3) 8 (143) 7 124 260 224 * - (133) 2012 (367) 1645 (1544) 3 - 158 2855 (2733) (1261) 30.09.2024 (Unaudited) 1326 196 (11) (152) (3) - 1 - 4 -* 1361 (3) 39 - (6) 1 (66) 3 32 - - - (63) 1298 (372) 926 (664) - - 152 1002 (949) (459) _,:;;-= f/..•:i' • 1/ h/ f/ _CJ I ✓ ,r' For the year ended 31.03.2025 (Audited) 2916 402 9 (295) (I) (4) 2 (2) 4 -* 3031 (582) (52) - (6) (9) (50) 7 95 - - - 43 2447 (824) 1653 (1438) -* 22 295 3541 (3224) (804)
Page 12
DIVl'S LABO RA TORIES LIMITED STATEMENT OF CONSOLIDATED UNAUDITED CASH FLOWS FOR THE HALF YEAR ENDED 30th SEPTEMBER 2025 (Rs. in Crores) For the Half year ended For the year ended Part iculars 30.09.2025 30.09.2024 31.03.2025 (Unaudited) (Unaudited) (Audited) C. Cash flow from financing activities Principal element of lease liabilities (2) -* (1) Proceeds /(repayment) of working capital loans (net) 83 5 - Interest paid (5) (1) (2) Dividend paid to company's shareholders (796) (796) (796) Net cash outflow from financing activities (720) (792) (799) Net increase/(decrease) in cash and cash equivalents (A+B+C) (336) (325) 50 Cash and cash equivalents at the beginning of the period/year 413 363 363 Cash and cash equivalents at end of the period/year 77 38 413 Reconciliation of cash and cash equivalents at the end of the period/ year Cash and cash equivalents as per Balance sheet Overdraft facilities from bank Balances as per Statement of cash flows * Amount is below the rounding off norms adopted by the group. Notes: 83 (6) 77 38 415 - (2) 38 413 1. The above Statement of Consolidated Unaudited Financial Results for the quarter and half year ended 30th September, 2025, Statement of Consolidated Unaudited Assets and Liabilities as at 30th September, 2025 and Statement of Consolidated Unaudited Cash Flows for the half year ended 30th September, 2025 ('Consolidated Statement') are prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations , 2015 as amended . This Consolidated Statement has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on November 07, 2025. The statutory auditors have carried out a limited review of this Consolidated Statement and issued an unmodified report thereon. 2. The Consolidated Unaudited Financial Results include the financial results of Divi's Laboratories Limited and its two subsidiaries Divis Laboratories (USA) Inc. and Divi's Laboratories Europe AG (Referred as the "Group") 3. The Group is engaged in the manufacture of Active Pharmaceutical ingredients, intermediates, and nutraceutical ingredients and the same constitutes single reportable business segment as per Ind AS 108. 4. The Group does not have any discontinued operations and the profit for the period represents the profits from continuing operations only. 5. Details of Forex gain are as given below: Quarter ended 30.09.2025 I 30.06.2025 I Forex gain 63 I 39 I Forex gain has been included in other income. (Rs. in Crores) Half Year ended Year ended 30.09.2024 30.09.2025 I 30.09.2024 31.03.2025 29 102 I 28 48 For Divi's Laboratories Limited ~ (L- Dr. Kiran S Divi Whole-time Director and Chief Executive Officer ¼oR-1 ... r: / I ) H'':)1_:-:·' ::.J /
Page 13
Price Waterhouse Chartered Accountants LLP Review Report To The Board of Directors M/s Divi's Laboratories Limited Divi Towers, 1-72/23(P)/303, Cyber Hills, Gachibowli, • Hyderabad, 500032 1. We have reviewed the consolidated unaudited financial results of Divi's Laboratories Limited (the "Parent") and its subsidiaries (the parent and its subsidiaries hereinafter referred to as the "Group") (refer Note 2 on the Consolidated Statement) for the quarter ended September 30, 2025 and the year to date results for the period April 01, 2025 to September 30, 2025 which are included in the accompanying Statement of Consolidated Unaudited Financial results for the quarter and half year ended September 30, 2025, the Statement of Consolidated Unaudited Assets and Liabilities as on that date and the Statement of Consolidated Unaudited Cash Flows for the half year ended on that date (the "Consolidated Statement"). The Consolidated Statement is being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations"), which has been initialled by us for identification purposes. 2. This Consolidated Statement, which is the responsibility of the Parent's Management and has been approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Consolidated Statement based on our review. 3. We conducted our review of the Consolidated Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Consolidated Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable. 4. The Consolidated Statement includes the results of the following entities: a) Divis Laboratories (USA) Inc. b) Divi's Laboratories Europe AG -' • ' • -- )v0 1 . . ,,:,c:) - ---- ..... ce Wat • artered Accountants LLP, Unit - 2B, 8th Floor, Octave Block, Block El, Parcel - 4, Salarpuria --.;;::---:... -;;-..-owledge City, Raidurg, Hyderabad, Telangana - 500081 T: +91 (40) 44246740 Registered office and Head office: 11 -A, Vishnu Oigamber Marg, Sucheta Bhawan, New Oelhi - 110002 Price Waterhouse (a Partnership Firm) converted into Price Waterhouse Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-5001) with effect from July 25, 2014. Post its conversion to Price Waterhouse Chartered Accountants LLP, its ICAI registration number is 012754N/NS00016 (ICAI registration number before conversion was 012754N)
Page 14
Price Waterhouse Chartered Accountants LLP 5. Based on our review conducted and procedures perlormed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Consolidated Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. 6. The consolidated unaudited financial results includes the interim financial information/ financial results of 2 subsidiaries which have not been reviewed/audited by their auditors, whose interim financial information/ financial results reflect total assets of Rs. 527 crores and net assets of Rs. 132 crbres as at September 30, 2025 and total revenue of Rs. 184 crores and Rs. 387 crores, total net loss after tax of Rs. 5 crores and Rs. 7 crores and total comprehensive income/ Ooss) of Rs. (0.57) crores and Rs. 0.37 crores for the quarter ended September 30, 2025 and for the period from April 01, 2025 to September 30, 2025, respectively, and cash flows (net) of Rs. 3 crores for the period from April 01, 2025 to September 30, 2025, as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial information / financial results are not material to the Group. Our conclusion on the Consolidated Statement is not modified in respect of the above matter. For Price Waterhouse Chartered Accountants LLP Firm Registration Number: 012754N/N500016 ~~~d'J"', N.K. Varadarajan Partner Membership Number: 90196 UDIN: 25090196BMRJSO8929 Place: Hyderabad Date : November 07, 2025
Page 15
@ii) DIVI'S LABORATORIES LIMITED CIN: L24110TG1990PLC011854 Registered Office: 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad - 500 032, Telangana, India, Phone: +91 40 66966300, email: cs@divislabs.com, website: www.divislabs.com PRESS RE.LEASE DATED NOVEMBER 07, 2025 Divi's .Laboratories earns a Consolidated Total Income off 2860 crores for Q2 of FY26 Consolidated Financial Results For the quarter ended 30 th eptember 2025 Di vi's Laboratories has earned a consolidated total income < 2860 crores for the quarter ended 30th September 2025 as against a consolidated total income of < 2444 crores for the corresponding quarter of the previous year. Profit before tax (PBT) for the quarter amounted to< 912 crores as against a PBT of< 722 crores for the corresponding quarter of the previous year. Profit after tax (PAT) for the quarter amounted to < 689 Crores as against a PAT of < 510 crores for the corresponding quarter of the previous year. For the current quarter, we have forex gain of< 63 crores as against a gain of <2 9 crores during the corresponding quarter of the previous year: For the Halfvear ended 30th September 2025 For the half year ended 30th September 2025 the Company earned a consolidated total income of < 5389 crores as against a consolidated total income of< 4640 crores during the corresponding half-year of the previous year. PBT for the current half year came to< 1645 crores as against< 1326 crores for the corresponding half year of the previous year. PAT for the current half year came to < 1234 crores as against < 940 crores for the corresponding half year of the previous year. For the current half-year we had a forex gain of< 102 crores against a gain of< 28 crores for the corresponding half year of the previous year. Standalone Financial Results On a standalone basis, the Company's earnings are given below: < in crores Particulars For the Quarter ended For the half year ended 30-09-2025 30-09-2024 30-09-2025 30-09-2024 Total Income 2806 2407 5282 4548 PBT 920 735 1667 1338 Tax Expense 224 217 414 390 PAT 696 518 1253 948 Forex Gain / (Loss): Particulars of forex gain for the period, on standalone basis, are given below: < in crores Particulars For the Quarter ended For the half year ended 30-09-2025 30-09-2024 30-09-2025 30-09-2024 Forex gain 64 27 103 26